Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naloxone Behind-the-Counter? Petition Could Help Push Action

This article was originally published in RPM Report

Executive Summary

The idea of “behind-the-counter” may be behind the times, but a request to put naloxone there could help push FDA’s existing interest in expanding access to the overdose antidote.

You may also be interested in...



FDA’s ‘Access’ Challenge Highlighted At Naloxone Meeting

‘Behind-the-counter’ placement of opioid overdose treatment doesn’t resonate with agency, even as it wants to broaden availability.

Naloxone Could Go OTC

A House hearing on prescription abuse highlighted a potential OTC switch: naloxone for opioid overdose.

CDER Director Sees Behind-The-Counter Switches As Best Bet

FDA drug center chief Janet Woodcock says behind-the-counter switches would be the most effective method to make Rx drugs available without prescriptions, particularly to help treat chronic conditions.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel